UCB (UCB) Stock Overview
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for UCB from our risk checks.
UCB Community Fair Values
Create NarrativeSee what 35 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
UCB SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €263.40 |
| 52 Week High | €289.50 |
| 52 Week Low | €129.35 |
| Beta | 0.23 |
| 1 Month Change | 4.94% |
| 3 Month Change | 2.85% |
| 1 Year Change | 79.31% |
| 3 Year Change | 207.85% |
| 5 Year Change | 233.59% |
| Change since IPO | 86,222.16% |
Recent News & Updates
Recent updates
UCB (EBR:UCB) Could Easily Take On More Debt
Nov 11
Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher
Oct 14UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing
Jul 17Why We Think UCB SA's (EBR:UCB) CEO Compensation Is Not Excessive At All
Apr 18UCB SA's (EBR:UCB) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Apr 17
BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology
UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.Shareholder Returns
| UCB | BE Pharmaceuticals | BE Market | |
|---|---|---|---|
| 7D | 1.9% | 0.2% | 2.4% |
| 1Y | 79.3% | 15.3% | 24.9% |
Return vs Industry: UCB exceeded the Belgian Pharmaceuticals industry which returned 19.7% over the past year.
Return vs Market: UCB exceeded the Belgian Market which returned 28.6% over the past year.
Price Volatility
| UCB volatility | |
|---|---|
| UCB Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in BE Market | 7.3% |
| 10% least volatile stocks in BE Market | 2.6% |
Stable Share Price: UCB has not had significant price volatility in the past 3 months compared to the Belgian market.
Volatility Over Time: UCB's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 9,765 | Jean-Christophe Tellier | www.ucb.com |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
UCB SA Fundamentals Summary
| UCB fundamental statistics | |
|---|---|
| Market cap | €50.14b |
| Earnings (TTM) | €1.56b |
| Revenue (TTM) | €7.74b |
Is UCB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UCB income statement (TTM) | |
|---|---|
| Revenue | €7.74b |
| Cost of Revenue | €1.99b |
| Gross Profit | €5.75b |
| Other Expenses | €4.19b |
| Earnings | €1.56b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 30, 2026
| Earnings per share (EPS) | 8.18 |
| Gross Margin | 74.29% |
| Net Profit Margin | 20.13% |
| Debt/Equity Ratio | 19.0% |
How did UCB perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/07 09:05 |
| End of Day Share Price | 2026/04/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
UCB SA is covered by 37 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Bourdot | Barclays |
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |